Literature DB >> 9158878

Prediction of the therapeutic dose for benzodiazepine anxiolytics based on receptor occupancy theory.

K Ito1, A Asakura, Y Yamada, K Nakamura, Y Sawada, T Iga.   

Abstract

Many benzodiazepines (BZPs) are now used as anxiolytics with nearly 200-fold variety of therapeutic doses. The variation of the doses of BZPs is due to differences both in their pharmacokinetics and in their receptor binding characteristics. The purpose of this study is to clarify the mechanism of the differences in therapeutic dose by retrospective analyses and to develop a system for the quantitative estimation of optimal doses of BZPs. The values of receptor dissociation constant (Kd), which indicates the binding affinity of each BZP at the receptor site, were obtained from a number of works based on in vitro binding experiments. The plasma unbound concentrations of the BZPs and their active metabolites were calculated using the reported values of their total plasma concentrations after average oral doses of the BZPs and the values of their plasma unbound fractions, which were also taken from the literature. There were log-linear relationships between the Kd values of BZPs and their average therapeutic doses or maximum plasma concentrations, but the correlation coefficients were relatively small (r < 0.77). In contrast, a good log-linearity (r = 0.96) was observed in the correlation between their Kd values and the effective plasma unbound concentrations considering the active metabolites. This finding indicates that the receptor occupancy after administration of therapeutic dose of BZPs is consistent (52.3 +/- 3.2%) among the BZPs. In this study, we also develop a possible system for estimating the appropriate doses of BZPs based on receptor occupancy theory.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9158878     DOI: 10.1002/(sici)1099-081x(199705)18:4<293::aid-bdd24>3.0.co;2-b

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  7 in total

1.  Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors.

Authors:  James K Rowlett; Snjezana Lelas; Walter Tornatzky; Stephanie C Licata
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

Review 2.  Development of translational pharmacokinetic-pharmacodynamic models.

Authors:  D E Mager; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  2008-03-26       Impact factor: 6.875

3.  Flavan-3-ol esters: new agents for exploring modulatory sites on GABA(A) receptors.

Authors:  Sebastian P Fernandez; Nasiara Karim; Kenneth N Mewett; Mary Chebib; Graham Ar Johnston; Jane R Hanrahan
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 4.  Biomarkers for the effects of benzodiazepines in healthy volunteers.

Authors:  S J de Visser; J P van der Post; P P de Waal; F Cornet; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

Review 5.  Scaling pharmacodynamics from in vitro and preclinical animal studies to humans.

Authors:  Donald E Mager; Sukyung Woo; William J Jusko
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

6.  Theory-based analysis of clinical efficacy of triptans using receptor occupancy.

Authors:  Kentaro Tokuoka; Risa Takayanagi; Yuji Suzuki; Masayuki Watanabe; Yasuhisa Kitagawa; Yasuhiko Yamada
Journal:  J Headache Pain       Date:  2014-12-08       Impact factor: 7.277

7.  Double-blind, placebo-controlled trial of mifepristone on cognition and depression in alcohol dependence.

Authors:  Kim Donoghue; Abigail Rose; Simon Coulton; Rachel Coleman; Joanna Milward; Thomas Philips; Colin Drummond; Hilary Little
Journal:  Trials       Date:  2020-09-16       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.